Why Asthma Research Matters Right Now
Asthma is not one disease with one mechanism. It is a collection of subtypes — allergic, eosinophilic, exercise-induced, obesity-related — and each responds differently to treatment. What works beautifully for one person might do almost nothing for another. This variability is exactly why research studies keep enrolling new participants year after year, long after the first generation of inhalers hit the market.
In 2025, Breztri Aerosphere became the first triple-combination therapy approved for asthma in patients 12 and older, based on Phase III trials that demonstrated meaningful improvements over dual therapy. That approval happened because thousands of volunteers across multiple states raised their hands and said, "I'll try." The pipeline remains active. Eli Lilly is currently recruiting for a Phase II study of brenipatide, an investigational treatment for moderate-to-severe asthma that spans 121 locations including sites in Tempe, Newport Beach, and Nashville. The American Lung Association's Airways Clinical Research Centers are running the TRIM study, testing whether roflumilast — a drug already used for COPD — can help adults with poorly controlled asthma and elevated BMI.
These are not fringe efforts. They represent a sustained push to expand the toolkit beyond inhaled corticosteroids and rescue inhalers.
The reality is that clinical trial eligibility criteria are often narrow by design. One analysis published in the Journal of Asthma found that only up to about 10 percent of real-world patients would have qualified for the biologic trials used to gain regulatory approval. That gap between research populations and everyday patients matters, and it is part of why newer studies are broadening their inclusion criteria.
What Happens Inside a Trial
Understanding the phases helps demystify the process. Phase I trials are small, sometimes just a few dozen healthy volunteers, focused on safety and dosage. Phase II expands to a few hundred patients and begins measuring whether the treatment actually works. Phase III can involve thousands of participants across multiple states and countries, generating the evidence that regulators rely on. Phase IV happens after approval, tracking long-term safety and real-world performance.
For someone with asthma, most opportunities fall into Phase II, III, or IV. A Phase II study like the brenipatide trial might ask participants to visit a clinic once a month for about a year, complete breathing tests, keep a symptom diary, and receive either the investigational drug or a placebo. A Phase IV study might compare two already-approved medications in a real-world setting, requiring fewer visits and less invasive monitoring.
The study medication and all study-related procedures are typically covered at no cost to the participant. Many trials also provide compensation for time and travel, though the amount varies by location, visit frequency, and study duration. The UVA Asthma and Allergy Clinical Research program, for instance, offers compensation for screening visits, while the Midwest Allergy Sinus Asthma group notes that qualifying participants receive compensation for time and reasonable expenses.
| Trial Type | Phase | Typical Duration | Who It May Suit | Key Considerations |
|---|
| Biologic injectable (e.g., tezepelumab, mepolizumab) | III–IV | 24–52 weeks | Adults with severe eosinophilic or allergic asthma | May involve self-injection training; regular blood draws |
| Oral small-molecule drug (e.g., roflumilast, brenipatide) | II–III | 12–52 weeks | Adults with uncontrolled moderate-to-severe asthma | Daily pill regimen; fewer clinic visits than injectables |
| Triple-combination inhaler | III–IV | 12–24 weeks | Patients 12+ on ICS/LABA seeking better control | Familiar inhaler format; may compare against dual therapy |
| Behavioral or lifestyle intervention | II–III | 8–24 weeks | Patients with obesity-related or exercise-induced asthma | May involve diet coaching, breathing exercises, or activity tracking |
| Pediatric-specific studies | II–III | 12–52 weeks | Children and adolescents 6–17 years | Parental consent required; extra monitoring; often fewer procedures |
How People Find Studies — and What They Worry About
Lena, a 42-year-old teacher in Durham, North Carolina, stumbled onto the TRIM study through a Facebook post from the Duke Asthma Allergy Airway Center. She had never considered research before. "I thought clinical trials were for people who had exhausted every option," she said. "I didn't realize you could participate while still taking your regular medications."
That misunderstanding is common. Most asthma trials are designed as add-on protocols — meaning participants continue their existing maintenance therapy while the investigational treatment is layered on top. Nobody is asked to stop their prescribed inhalers and cross their fingers.
The bigger concern for many Americans is logistical. How many visits? How far is the site? A study with 121 locations scattered across the country is more accessible than one with five sites concentrated in major coastal cities. ClinicalTrials.gov, maintained by the National Library of Medicine, lists every registered study along with site locations, eligibility criteria, and contact information. The American Lung Association also maintains a searchable directory of trials at its Airways Clinical Research Centers, which include sites in Illinois, New York, North Carolina, and Vermont.
For those searching "asthma clinical trials near me," the first step is often filtering by state and city on these platforms. A search for "asthma" and "recruiting" on ClinicalTrials.gov returns hundreds of results, but narrowing by distance, age group, and asthma severity makes the list manageable. The key is being specific: a trial for mild allergic asthma may not accept someone with severe persistent asthma, and vice versa.
Another hesitation people voice is the placebo concern. "What if I get the sugar pill?" The answer depends on the study design. In many asthma trials, all participants receive standard-of-care treatment. The investigational arm adds the experimental drug on top of that baseline. In other designs, particularly Phase II dose-ranging studies, there may be a placebo group, but trial protocols include rescue plans and close monitoring. Before enrolling, every participant goes through an informed consent process where the study team explains exactly what the design involves, including the probability of receiving placebo.
Who Runs These Studies and Where
Academic medical centers, pharmaceutical companies, and nonprofit research networks all sponsor asthma trials. The University of Virginia's Division of Asthma, Allergy, and Immunology runs screening protocols to build a registry of potential participants for future studies. The Icahn School of Medicine at Mount Sinai in New York and Northwestern University in Chicago both operate dedicated airway disease research centers. These are not fly-by-night operations. They are embedded in hospitals and clinics with institutional review boards that scrutinize every protocol before a single patient is enrolled.
Safety monitoring continues throughout the study. If a data safety monitoring board detects an unexpected pattern of adverse events, the trial can be paused or stopped. This happens rarely, but the mechanism exists precisely to protect participants.
For people with severe asthma who have cycled through multiple biologics without lasting relief, clinical trials can offer access to therapies that are years away from pharmacy shelves. It is not a guarantee of improvement — no honest researcher would promise that — but it is a structured opportunity to try something different under close medical supervision.
Taking the Next Step
If any of this resonates, the practical path forward is straightforward. Start by talking to your pulmonologist or allergist. Many specialists are connected to research networks and can flag studies that match your profile. If your doctor is not plugged into research, you can search on your own.
Visit ClinicalTrials.gov and enter "asthma" along with your city or state. Use the filters to narrow by recruitment status (look for "recruiting" or "not yet recruiting"), age group, and phase. Read the eligibility criteria carefully — they are listed under each study and spell out exactly who qualifies. If you see a match, call or email the study coordinator listed on the page. That person's job is to answer questions and walk you through the screening process.
You can also check the American Lung Association's clinical trials directory, which focuses on respiratory research and tends to list studies with a strong safety track record. Their ACRC network includes some of the most respected asthma research centers in the country.
Before you commit to anything, ask the study team these questions: How many visits are required and how long does each one last? Are there any out-of-pocket costs for parking, transportation, or procedures? What happens if my asthma worsens during the study? Can I withdraw at any time? The answers should be clear and documented in the informed consent form.
Clinical trials are not for everyone. They require time, patience, and a tolerance for uncertainty. But for millions of Americans whose asthma disrupts sleep, sidelines exercise, and steals days to urgent care, they represent something that standard treatment pathways sometimes cannot: forward motion.
研究の知恵